Evidence map›Paper›PMID 23944748›Full record

ArticleJournal of medicinal chemistry2013

A fundamental relationship between hydrophobic properties and biological activity for the duocarmycin class of DNA-alkylating antitumor drugs: hydrophobic-binding-driven bonding.

Amanda L Wolfe, Katharine K Duncan, James P Lajiness, Kaicheng Zhu, Adam S Duerfeldt, Dale L Boger

Abstract read
In one paragraph

Article in Journal of medicinal chemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Supernatural Products.The Chemist · 2025
    Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Amanda L WolfeDepartment of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute , 10550 North Torrey Pines Road, La Jolla, California 92037, United States.
Katharine K Duncan
James P Lajiness
Kaicheng Zhu
Adam S Duerfeldt
Dale L Boger

Funding

ANTITUMORE ANTIBIOTICS: STREPTONIGRIN AND LAVENDAMYCINR01CA042056 · NCI · SCRIPPS RESEARCH INSTITUTE, THE · PI BOGER, DALE L · 1985 to 2024
$10.6M
THE ANTITUMOR ANTIBIOTICS CC-1065 AND THE DUOCARMYCINSR01CA041986 · NCI · SCRIPPS RESEARCH INSTITUTE, THE · PI BOGER, DALE L · 1985 to 2011
$4.0M
NCI NIH HHS CA041986NCI NIH HHS CA042056NCI NIH HHS R01 CA041986NCI NIH HHS R01 CA042056
6 · The paper itself

Abstract

Two systematic series of increasingly hydrophilic derivatives of duocarmycin SA that feature the incorporation of ethylene glycol units (n = 1-5) into the methoxy substituents of the trimethoxyindole subunit are described. These derivatives exhibit progressively increasing water solubility along with progressive decreases in cell growth inhibitory activity and DNA alkylation efficiency with the incremental ethylene glycol unit incorporations. Linear relationships of cLogP with -log IC50 for cell growth inhibition and -log AE (AE = cell-free DNA alkylation efficiency) were observed, with the cLogP values spanning the productive range of 2.5-0.49 and the -log IC50 values spanning the range of 11.2-6.4, representing IC50 values that vary by a factor of 10(5) (0.008 to 370 nM). The results quantify the fundamental role played by the hydrophobic character of the compound in the expression of the biological activity of members in this class (driving the intrinsically reversible DNA alkylation reaction) and define the stunning magnitude of its effect.

Indexed as

AnimalsAntineoplastic Agents, AlkylatingBinding SitesCell Line, TumorDNADuocarmycinsHydrophobic and Hydrophilic InteractionsIndolesInhibitory Concentration 50Magnetic Resonance SpectroscopyMicePyrrolesSolubilitySpectrometry, Mass, Electrospray IonizationAntineoplastic Agents, AlkylatingDNADuocarmycinsduocarmycin SAIndolesPyrroles

Identifiers

PMID23944748
PMCPMC3793852

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.